Small study aims to perfect bleeding drug dose for joint replacements
NCT ID NCT05075200
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This completed Phase 2 trial studied how the drug tranexamic acid (TXA) is processed in the body during hip or knee replacement surgery. 21 adults received a standard dose of TXA, and researchers measured drug levels in the blood to build a model for optimal dosing. The goal is to reduce blood loss and the need for transfusions after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHROPLASTY, REPLACEMENT, KNEE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tranexamic acid
What this could lead to
If successful, this could lead to better dosing guidelines for tranexamic acid during joint replacement surgery, helping reduce blood loss and the need for transfusions.
What could go wrong
This was a small, early-phase study with only 21 participants, so results may not apply to all patients. The focus was on drug levels in the blood, not on direct patient outcomes like reduced transfusions.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.